Novartis' Cosentyx wins CHMP backing for adolescent hidradenitis suppurativa
NVS•Novartis received a positive CHMP opinion for Cosentyx in patients aged 12 and older with moderate to severe hidradenitis suppurativa. A European Commission decision is expected in approximately two months.
1. CHMP recommendation
The recommendation covers adolescents with active disease who responded inadequately to conventional systemic therapy. If the European Commission approves it, Cosentyx would be Europe's only IL-17A inhibitor for adolescent hidradenitis suppurativa.
